Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify pain-generating discs in chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. Based in Beverly Hills, this private practice is known for its expertise in complex spinal procedures and early adoption of innovative technologies. The inclusion of a private practice site reflects growing interest in integrating Nociscan into real-world clinical workflows beyond academic medical centers.
Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery and a neurosurgeon with over 25 years of experience, emphasized the importance of precision in spine surgery. "Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot," he said. "The CLARITY trial is designed to evaluate how this technology can enhance clinical decision-making. Matching the right procedure to the right patient is what moves the field forward."
The CLARITY trial is a prospective, randomized, multi-center study involving 300 patients undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS at 12 months. Aclarion anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
Ryan Bond, Chief Strategy Officer of Aclarion, noted that private practice spine surgeons treat the majority of chronic low back pain patients. "The inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice," he said. Chronic low back pain affects approximately 266 million people worldwide, and Nociscan is the first evidence-supported SaaS platform to noninvasively distinguish painful from nonpainful discs. When all Nociscan-positive discs are treated, the technology demonstrates a 97% surgical success rate.
For more information about the CLARITY trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
